Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation in unresectable stage III NSCLC
2006-004726-91Phase 3Terminated
- Sponsor
- CHU de Lille
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CHU de Lille. Primary endpoint: Overall survival. Started Mar 2009; status: terminated.
02
Drugs
docetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-004726-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004726-91.